216 related articles for article (PubMed ID: 33039456)
1. Macrophage polarization contributes to the efficacy of an oncolytic HSV-1 targeting human uveal melanoma in a murine xenograft model.
Liu S; Zhang J; Fang S; Zhang Q; Zhu G; Tian Y; Zhao M; Liu F
Exp Eye Res; 2021 Jan; 202():108285. PubMed ID: 33039456
[TBL] [Abstract][Full Text] [Related]
2. Antitumor efficacy of oncolytic HSV-1 expressing cytosine deaminase is synergistically enhanced by DPD down-regulation and EMT inhibition in uveal melanoma xenograft.
Liu S; Zhang J; Fang S; Su X; Zhang Q; Zhu G; Zhu L; Zhao M; Liu F
Cancer Lett; 2020 Dec; 495():123-134. PubMed ID: 32946963
[TBL] [Abstract][Full Text] [Related]
3. Enhancing the immune effect of oHSV-1 therapy through TLR3 signaling in uveal melanoma.
Liu S; Li M; Sun F; Zhang J; Liu F
J Cancer Res Clin Oncol; 2023 Feb; 149(2):901-912. PubMed ID: 36030435
[TBL] [Abstract][Full Text] [Related]
4. Antitumor Efficacy of Oncolytic Herpes Virus Type 1 Armed with GM-CSF in Murine Uveal Melanoma Xenografts.
Liu S; Liu F; Zhao M; Zhang J
Cancer Manag Res; 2020; 12():11803-11812. PubMed ID: 33239914
[TBL] [Abstract][Full Text] [Related]
5. Herpes Simplex Virus 1 Infection Promotes the Growth of a Subpopulation of Tumor Cells in Three-Dimensional Uveal Melanoma Cultures.
Valyi-Nagy T; Fredericks B; Ravindra A; Hopkins J; Shukla D; Valyi-Nagy K
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045986
[TBL] [Abstract][Full Text] [Related]
6. Role of tumor invasiveness, the extracellular matrix, and chromatin sequestration in the susceptibility of uveal melanoma to herpes simplex virus type 1.
Valyi-Nagy K; Folberg R; Valyi-Nagy T; Maniotis AJ
Exp Eye Res; 2007 May; 84(5):991-1000. PubMed ID: 17386925
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.
Meisen WH; Wohleb ES; Jaime-Ramirez AC; Bolyard C; Yoo JY; Russell L; Hardcastle J; Dubin S; Muili K; Yu J; Caligiuri M; Godbout J; Kaur B
Clin Cancer Res; 2015 Jul; 21(14):3274-85. PubMed ID: 25829396
[TBL] [Abstract][Full Text] [Related]
8. Effect of oncolytic ECHO-7 virus strain Rigvir on uveal melanoma cell lines.
Tilgase A; Grīne L; Blāķe I; Borodušķis M; Rasa A; Alberts P
BMC Res Notes; 2020 Apr; 13(1):222. PubMed ID: 32299493
[TBL] [Abstract][Full Text] [Related]
9. An Infrared Dye-Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma.
Kines RC; Varsavsky I; Choudhary S; Bhattacharya D; Spring S; McLaughlin R; Kang SJ; Grossniklaus HE; Vavvas D; Monks S; MacDougall JR; de Los Pinos E; Schiller JT
Mol Cancer Ther; 2018 Feb; 17(2):565-574. PubMed ID: 29242243
[TBL] [Abstract][Full Text] [Related]
10. Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy.
Ghonime MG; Cassady KA
Cancer Immunol Res; 2018 Dec; 6(12):1499-1510. PubMed ID: 30352799
[TBL] [Abstract][Full Text] [Related]
11. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
12. [The Advances of Oncolytic Herpes Simplex Virus in Cancer Therapy].
Hao M; Huang C; Xia N
Bing Du Xue Bao; 2016 Jul; 32(4):516-22. PubMed ID: 29996042
[TBL] [Abstract][Full Text] [Related]
13. Identification of virus resistant tumor cell subpopulations in three-dimensional uveal melanoma cultures.
Valyi-Nagy K; Dosa S; Kovacs SK; Bacsa S; Voros A; Shukla D; Folberg R; Valyi-Nagy T
Cancer Gene Ther; 2010 Apr; 17(4):223-34. PubMed ID: 19893596
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo.
Yoo JY; Swanner J; Otani Y; Nair M; Park F; Banasavadi-Siddegowda Y; Liu J; Jaime-Ramirez AC; Hong B; Geng F; Guo D; Bystry D; Phelphs M; Quadri H; Lee TJ; Kaur B
Neuro Oncol; 2019 Sep; 21(9):1131-1140. PubMed ID: 31063549
[TBL] [Abstract][Full Text] [Related]
15. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
[TBL] [Abstract][Full Text] [Related]
16. Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors.
Maldonado AR; Klanke C; Jegga AG; Aronow BJ; Mahller YY; Cripe TP; Crombleholme TM
J Gene Med; 2010 Jul; 12(7):613-23. PubMed ID: 20603890
[TBL] [Abstract][Full Text] [Related]
17. The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma.
Zhu W; Lv J; Xie X; Tian C; Liu J; Zhou H; Sun C; Li J; Hu Z; Li X
Immunol Lett; 2022 Jan; 241():15-22. PubMed ID: 34774916
[TBL] [Abstract][Full Text] [Related]
18. Antitumor efficacy of VP22-CD/5-FC suicide gene system mediated by lentivirus in a murine uveal melanoma model.
Liu S; Song W; Liu F; Zhang J; Zhu S
Exp Eye Res; 2018 Jul; 172():144-151. PubMed ID: 29660328
[TBL] [Abstract][Full Text] [Related]
19. Unlocking the potential of dimethyl fumarate: enhancing oncolytic HSV-1 efficacy for wider cancer applications.
Alwithenani A; Taha Z; Thomson M; Chen A; Wong B; Arulanandam R; Diallo JS
Front Immunol; 2023; 14():1332929. PubMed ID: 38169670
[TBL] [Abstract][Full Text] [Related]
20. The oncolytic virus H101 combined with GNAQ siRNA-mediated knockdown reduces uveal melanoma cell viability.
Li Y; He J; Qiu C; Shang Q; Qian G; Fan X; Ge S; Jia R
J Cell Biochem; 2019 Apr; 120(4):5766-5776. PubMed ID: 30320917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
